Dear Liver Health Community,

This past year has been one of tremendous turmoil across the world, but it has also been a time of generosity, fortitude and empathy. Throughout the pandemic and the transition to a fully virtual work environment, we learned to look within ourselves and to those we could count on for support—our community. On behalf of the Global Liver Institute (GLI) team, I want to thank our partners and dedicated advocates for working tirelessly with us throughout 2020 to support the needs of liver patients, especially during the more trying days.

Throughout 2020, the GLI team stayed focused on our goal to improve the lives of the half a billion people around the world who are living with more than 100 different types of liver diseases. We’re fortunate and grateful that the organization continues to expand in size in terms of staff, geographic reach and the impact we’re making around the world.

GLI nimbly shifted to virtual formats in 2020 for all our events, which further expanded our reach. Our virtual International NASH Day engaged 80 partner organizations in 26 countries and received the endorsement of the American Association for the Study of Liver Diseases and the European Association for the Study of Liver Diseases. And through our virtual Advanced Advocacy Academy, we trained 52 advocates from 5 continents, including from 11 countries and 22 U.S. states.

In response to the pandemic, GLI offered specialized COVID-19 information tailored specifically to patients with liver disease and hosted a weekly live show to discuss the challenges facing the liver health community. We also sought to ensure patients with liver disease were included in public policies addressing COVID-19 while continuing our additional efforts to support legislative and regulatory approaches that would benefit the liver health community.

Our programming focused on specific liver diseases also continued to flourish. Our Liver Cancer program experienced massive growth as we added plain language patient guidance, educational videos, webinars and discussions with expert guests. The GLI nonalcoholic steatohepatitis (NASH) program launched the Beyond the Biopsy initiative dedicated to accelerating the acceptance and adoption of non-invasive diagnostics as an alternative to biopsy. On top of this, GLI launched the Pediatric and Rare Liver Diseases Council, which now has more than 25 member organizations.

In 2021, we will continue to commit ourselves to the care, the attention and the services that the liver health community needs to not only survive but thrive. Thank you for your support in 2020. We look forward to working with you in 2021 and beyond to support patients with liver disease worldwide.

Sincerely,

[Signature]

Donna R. Cryer, JD
President & CEO
Global Liver Institute
Changing the World of Liver Health

With offices in the United States and Europe, GLI is the only patient-led liver health nonprofit operating internationally.

Mission
To improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases.

Vision
For liver health to take its proper place on the global public health agenda consistent with its prevalence and impact.

2020 Staff
- Donna R. Cryer, JD
  President & CEO
- Larry Holden
  Chief of Staff
- Richard Gelula
  Chief Development Officer
- Ivy Ahmed
  Liver Cancers Program Director
- Livia Alimena
  EU Office Director, IND Director
- Jana Bernard
  Social Media Manager
- Jen DelGrande
  A3 Program Director
- Carrie Gelula
  Brand Director
- Whitney Gray
  NASH Communications Manager
- Jeff McIntyre
  NASH Program Director
- Andrew Scott
  Policy Director
- Elisabeth Vogel
  Liver Cancers Program Coordinator
- Nicole Wells
  Pediatric and Rare Program Manager
- Danielle Wivel-Wagner
  Operations Manager

2020 Board of Directors
- Hillel Tobias, MD, PhD
  NYU School of Medicine, Chair
- Donna R. Cryer, JD
  President & CEO
- Andrew Cameron, MD, PhD
  Johns Hopkins School of Medicine, Secretary
- Victor J. Reyes, MBA
  Deloitte Consulting, Treasurer
- Dennis R. Cryer, MD, FAHA
  CyverHealth, LLC
- Brian Harvey, MD, PhD
  US FDA (Ret.)
- Warren A. Jones, MO
  Hampton University
- Lewis R. Roberts, MB, ChB, PhD
  Mayo Clinic
- Rohit Satoskar, MD
  Medstar Georgetown University Medical Center
- Amita Shukla, MBA
  Vitamina
- Melanie Thomas, MD, MSc
  Duke Health
Office of the CEO

Having experienced incredible growth in the previous two years, and facing the retirement of our long-term COO, we took the opportunity in 2020 to reorganize and strengthen the organization by creating the Office of the CEO. Composed of the President and Chief Operating Officer, Executive Assistant, and new positions of Chief of Staff and Operations Manager, the Office of the CEO deepened the organization’s ability to focus attention on building a financial, legal, and information technology infrastructure to match and scale with its programs. These efforts allowed the organization to pivot and expand rapidly, anticipating and responding to a global COVID-19 pandemic, racial reckoning and change of administration in the United States. Two strategic and one condition-specific initiatives launched from the Office of the CEO, which also serves as our innovation incubator – the Diversity, Equity and Belonging Portfolio; GLI COVID-19 Response Program; and the Pediatric and Rare Liver Diseases Council. We believe that these actions have allowed us to serve the expanding GLI team, the community of liver health organizations, and patients more creatively and more sustainably.

Diversity, Equity and Belonging

GLI is fundamentally committed to achieving health equity. Longstanding, deep embedded, systematic issues create barriers for liver patients in almost every setting and circumstance, and we recognize the disproportionate burden and impact on patients, families, and communities of color exacerbated by COVID-19. High levels of stigma, compounded by economic challenges, immigration status, biases in care delivery, disparities in digital technology access, and insurance all contribute to poorer health outcomes for certain segments of the population. Our leadership applied their extensive experience in multicultural health and health disparities reduction to an analysis of our governance, employment practices, and programs for opportunities to demonstrate best-in-class approaches to our portfolio of diversity, equity, and belonging practices (since we believe it is insufficient to simply include people, but to create structures and cultures so people are confident they belong in an organization and their full and authentic selves are welcomed). Our CEO advised many external organizations throughout healthcare on their diversity response and strategic planning.

GLI worked consistently and collaboratively with other organizations and coalitions. Our policy agenda reflected our focus and included:

- The Social Determinants of Health Act
- The Health Equity and Accountability Act
- The Building COVID-19 Vaccine Confidence Act
COVID-19 Response Program for Liver Patients

In March 2020, GLI launched the COVID-19 Response Program for Liver Patients for patients with liver disease, liver transplant, liver cancer, or who are immunosuppressed or otherwise at high risk for COVID-19. The GLI COVID-19 Response Program for Liver Patients consisted of free updates on scientific and social issues, weekly GLI Live interviews streamed online, and a staffed community question and answer inbox.

Along with the COVID-19 Response Program for Liver Patients, GLI focused advocacy efforts on ensuring patients in every community are protected during COVID-19, whether that is from the virus, or to ensure consistent access to care during the pandemic. GLI signed on to letters in support, advocated for on Capitol Hill in meetings, and more. GLI conducted a COVID-19 Patient Access Survey.

GLI LIVE

Launched as part of our comprehensive COVID-19 response program for liver patients, GLI LIVE provided an outlet to increase connectivity among the liver community through engaging conversations and discussion on a variety of timely topics. Donna Cryer, GLI Founder and CEO, hosted these weekly events starting in March, 2020, featuring lively dialogue and interesting perspectives from expert guests. During the time of physical distancing, it was critical to take actions that help people who would like to feel and stay socially connected to each other. The show was streamed live every Wednesday at 12 pm ET on Facebook, YouTube, and Periscope. In 2020, GLI hosted 34 episodes of GLI LIVE and posted 13 COVID-19 articles.

Pediatric & Rare Diseases Council

GLI planned the Pediatric and Rare Liver Diseases Council throughout 2020, recruiting founding member organizations, obtaining grant support and recruiting an alumna of GLI’s Advanced Advocacy Academy as the program manager. The council brings together non-profit, for-profit, government and patient representatives who are committed to addressing the challenges and impact of pediatric and rare liver diseases on individuals, communities and organizations around the world. GLI launched the council with 27 member organizations at its inaugural meeting in November 2020.

Goals of the Pediatric and Rare Liver Diseases Council

• Elevate the visibility and voice of the pediatric and rare liver diseases community.
• Strengthen the organizational infrastructure of pediatric and rare liver diseases organizations.
• Advance the policy agenda in pediatric and rare liver diseases.
• Identify common elements to accelerate research in pediatric and rare liver diseases.

Pediatric & Rare Diseases Council Impact

• First-ever collaborative assembly of stakeholders addressing pediatric and rare liver diseases.
• Created an agenda to address policy, research, education and other key cross-cutting factors affecting pediatric and rare liver disease patients.
• Established 2021 plans including a landscape report of organizations in the pediatric and rare diseases space and workgroups on policy, research and education.
International NASH Day

In 2020, GLI hosted our largest International NASH Day yet, with more than 80 partners from around the world. For the first time, NASH Day was endorsed by the major hepatology organizations in the U.S. and Europe – AASLD and EASL.

International NASH Day Impact

- GLI and its partners educated millions of people around the world about NASH.
- Local organizations reached out to people in their communities.
- Six panels brought together leading experts in the NASH field to discuss treatment and care for patients with NASH and prevention strategies.
- Through the first Virtual NASH Day Hill Day, GLI and advocates contacted more than 15 Congressional offices in the U.S. House of Representatives and Senate to support the LIVER Act and ask for its inclusion in the COVID-19 response package.

International NASH Day At a Glance

- 6 virtual NASH educational panels
- New website
- 3 patient brochures translated into 12 languages
- 25 expert international speakers
- 18,034 virtual panel views
- 293,764,030 mat release unique visitors
- 44 million: press release reach
- 11 million cumulative radio airings
- 15 million #NASHday impressions

Learn more about International NASH Day at www.International-NASH-Day.com
NASH Programs

NASH is a global public health challenge that is increasing in prevalence, and GLI is dedicated to turning that tide. This year’s heightened focus on healthcare has provided the opportunity for the liver health community to work collaboratively across specialty areas to examine how countries are addressing NAFLD and NASH. Thus, even in a year of great challenge, GLI made great strides in our work to increase awareness, diagnostic options and treatments for NASH.

NASH Programs Impact

- Established consistent and meaningful terminology for communication and collaboration in all areas around NASH globally.
- Set an agenda and detailed NASH roadmap with actionable recommendations for each stakeholder group impacted by NASH.
- Launched an online resource center with CME/CE-certified video modules, expert commentaries and downloadable presentations and resources targeted toward advanced practice clinicians in hepatology, gastroenterology, endocrinology and primary care. The resource aims to improve provider understanding of NASH diagnosis, management and emerging treatments.

U.S. NASH Action Plan

GLI and the GLI NASH Council released the U.S. NASH Action Plan to comprehensively address NASH and its impact on patients and families, public health and the economy. The plan includes actionable recommendations specifically for each stakeholder group involved in NASH prevention and treatment, including patients and caregivers, clinicians, patient advocacy organizations, medical societies, industry, policymakers, regulators, health systems and health insurance payers.

The Language of NASH

In September 2020, GLI shared a new resource, The Language of NASH, to unite the liver community in its communication about NAFLD and NASH. This framework helps physicians, patients, caregivers, families and advocates use consistent wording to send a clear message: it is time to increase awareness, diagnosis and treatment options for NASH.

NASH Council

The purpose of the NASH Council is to shine a spotlight and coalesce an expansive set of stakeholders around the urgency of developing mechanisms for quantifying and addressing the epidemic of NAFLD and NASH in the U.S. and abroad. The NASH Council convenes twice per calendar year and may create workgroups to advance and develop specific concepts and programs. In 2020, the GLI NASH Council grew to more than 70 member organizations and expanded its global reach, welcoming new member organizations and partners in pharmacology, diagnostics, medical societies, patient organizations, research and NGOs.

Beyond the Biopsy

In September 2020, GLI launched the Beyond the Biopsy initiative to promote awareness and education about the use of non-invasive diagnostics as an alternative to biopsies. The initiative encourages advocates to support greater adoption of non-invasive diagnostics legislative, regulatory and coverage/reimbursement changes.

The launch of the initiative included a national radio tour and virtual panels focusing on three states (Colorado, Massachusetts and New York) with leading experts, policymakers and patient advocates featured as speakers.

Beyond the Biopsy At a Glance

- 2 public statements from Members of Congress
- 4 Beyond the Biopsy Educational Panels
- National Radio Media Tour: 1,000 radio and online airings, with a 11.8M cumulative audience
- Social Media: 988,800 #BeyondtheBiopsy impressions
- MAT Article: 246.7M unique visitors from 2,500 Placements

Read the U.S. NASH Action Plan and The Language of NASH at www.globalliver.org/resources#nash

Learn more about Beyond the Biopsy at www.globalliver.org/beyond
Advanced Advocacy Academy

The week-long event was held virtually on a digital learning platform, and was constructed to introduce participants to a broad set of advocacy areas in which they could focus their future liver advocacy endeavors. These areas included digital advocacy, policy and legislation, clinical trials, research and development, patient engagement projects, healthcare delivery, media and storytelling, social media and more. A3 is the first step in GLI’s ongoing training and support for liver patients, caregivers, and professionals, which provides them with the information, skills, allies and opportunities they need to effectively advocate for liver health.

On October 26-30, 2020, GLI successfully held its fourth annual Advanced Advocacy Academy (A3), a five-day virtual event designed to train a force of expert liver health advocates. Targeted towards liver patients, caregivers and professionals, A3 builds the advocacy knowledge and skills needed to advocate for liver health.

A3 Advocates engaged in over 19 hours of live online sessions with expert speakers via GLI’s virtual learning platform.

A3 2020 at a Glance
- 52 advocates
- 5 continents, 11 countries, and 22 U.S. states
- Over 19 hours of live online sessions
- 11 speakers

A3 Impact
- Liver patients trained by GLI are impacting policymakers across the globe.
- A3 alumni participated in webinars throughout the year on digital health, social media, media campaigns, liver research, and more.
- Media appearances from A3 advocates in nationwide and international magazines, podcasts, radio shows, blogs, and social media campaigns.

Learn more about GLI’s Advanced Advocacy Academy at www.Globalization.org/A3
Liver Cancer Programs

Liver cancer is a global public health threat. In addition, liver cancer is one of the few cancer types with increasing incidence and mortality rates and will account for over 700,000 deaths worldwide this year alone.

Liver Cancer Programs Impact

- Convened liver cancer stakeholders from across the globe in the Liver Cancers Council to improve the lives of liver cancer patients.
- Created the first suite of evidence-based patient education materials addressing liver cancer via video, digital content, and using social media. This was the first educational program of its kind.
- Elevated the global dialogue about liver cancer through a robust #OctoberIs4Livers education and awareness program that reached more than 100 million people.

Liver Cancers Council

With more than 20 member organizations, GLI’s Liver Cancers Council brings together committed stakeholders across the liver cancer community to improve the liver cancer experience. The council is made up of advocacy partners, healthcare professionals, patients, survivors, partners and advocates.

Liver Cancer Lessons

To address the limited information available online for people impacted by liver cancers, GLI created evidence-based information for patients. This new content will serve as the basis for continued online growth and expansion of educational materials in a variety of accessible formats. This was the first educational program of its kind.

#OctoberIs4Livers

The #OctoberIs4Livers (#O4L) education and awareness campaign is a unique program that focuses on liver cancers. Throughout the month of October, liver cancer patients, survivors, caregivers, healthcare providers, patient advocates, partner organizations, academic institutions, corporate partners and others come together to elevate the global dialogue about liver cancers.

At a Glance

- 100 million people reached
- 78 signatories on proclamation representing 17 countries and continuing to grow
- Number of placements in media outlets: total pickup was 82 and engagement actions was 199
- Number of proclamations signatories: 78 signatories representing 17 countries
- Number of social media engagements: more than 15,000
- Number of program participants: more than 50 registrations and attendees for a Candid Conversations Workshop, a program that brought together a clinician, caregiver and social worker to discuss liver cancer
- GLI collaborated with artist Kristina Hagman, the daughter of liver transplant recipient and actor Larry Hagman (J.R. Ewing in Dallas) to create a design for t-shirts, sweatshirts and other items to support raising funds for liver disease and liver cancer awareness.

Learn more about GLI’s Liver Cancer Programs at www.GlobalLiver.org/liver-cancer
GLI worked at the national and global level to shape public policy. GLI promotes innovation, encourages collaboration across sectors, and implements optimal legislative and regulatory approaches that are patient-centric to advance liver disease to its rightful place on the national and global public health agenda.

2020 GLI Policy Impact

The U.S. NASH Action Plan, released in December 2020, includes a comprehensive set of actionable recommendations for the full spectrum of individuals and entities involved in NASH prevention and treatment. The plan provides a road map for NASH patients, advocates, practitioners, and payors for years to come. In short order, GLI yielded several significant policy gains under the NASH Action Plan:

- The congressional introduction of the NASH Care Act of 2020, preparing the U.S. healthcare system for therapies, coverage, and the delivery of care for patients with all stages of NASH. The introduction sets an important marker on NASH policy to advance, as the two bipartisan sponsors in the U.S. House of Representatives were on the key committee and subcommittee of jurisdiction.

- The inclusion of nonalcoholic fatty liver disease within the new Centers for Disease Control and Prevention Diabetes Resources. CDC recognition of this condition within a diabetes initiative increases understanding of diabetes as a key comorbidity for fatty liver diseases, an important step toward prevention and diagnosis.

- The inclusion of hepatic fibrosis coding revisions to the FY 2021 ICD-10-CM, a system used by physicians and other healthcare providers to classify and code all diagnoses, symptoms and procedures recorded in conjunction with hospital care in the United States. This update allows for the coding of NASH that is both early and advanced, allowing for any future treatment to correlate with more precise diagnostic data than before.

Liver Action Network

GLI began building its liver digital advocacy platform, the Liver Action Network, to allow for more consistent advocacy opportunities for liver patient advocates, even amidst a global public health crisis. The network connects advocates with their members of Congress and federal agencies on vital policy priorities. Network successes included urging members of Congress to sign a bipartisan letter to the U.S. Department of Health and Human Services requesting more accountability in the Organ Procurement Organization system. The agency finalized a rule favoring the advocates’ position.

CDC Summit

GLI led a virtual Liver Cancer and Liver Disease Summit with the Centers for Disease Control and Prevention. The summit convened multiple divisions at the agency, strengthening the profile of liver disease and liver cancer within the agency and creating a network for continued collaboration for patient benefit.

Sign up for monthly policy news and updates from GLI at www.GlobalLiver.org/subscribe and view GLI’s 2021 agenda at www.GlobalLiver.org/policy
Communications

GLI’s Communications Department amplifies the impact of GLI’s programs and facilitates the flow of information between GLI and the public through GLI’s website, social media channels, events, press releases, and more. The department builds and maintains strong personal connections to the patients we serve and their caregivers and families. Additionally, the department maintains relationships with physicians, partners and professionals in the liver health field to raise liver health to its rightful place on the global public health agenda.

Channels

Website
GLI’s websites, GlobalLiver.org and NASHday.com are the ultimate destinations for liver health resources, GLI updates, and world news affecting the liver health community.

Newsletters
GLI sends out two monthly newsletters and special edition COVID-19 updates to a robust list of subscribers. GLI’s newsletters consistently get high open and click rates, exceeding the averages for nonprofit organizations.

Shop for a Cause
GLI collaborated with artist Kristina Hagman, the daughter of liver transplant recipient and actor Larry Hagman (J.R. Ewing in Dallas) to create a design for t-shirts, sweatshirts and other items to support raising funds for liver disease and liver cancer awareness. Look for more GLI-branded cause-related items in the future.

Videos & Live Streams
GLI LIVE every Wednesday discusses timely topics with expert guests and reaches thousands of viewers.

Traditional Media
GLI sends news releases to an ever-expanding list of news reporters. Donna Cryer conducts interviews with both health specific and mainstream news outlets. From January 2020 to December 2020, GLI outreach earned 1,821 media hits with a potential reach of 626.7 million readers and viewers.

Top topics included a push to cap Medicare beneficiaries’ out-of-pocket prescription drug costs amid the pandemic, a call for a more robust response from the U.S. Centers for Disease Control and Prevention to COVID-19, an effort to spare liver disease patients from disproportionate pandemic effects, and coverage of unnecessary patient deaths from organ donation policy failures. Source: Meltwater media monitoring

Social Media
GLI uses social media to engage with patients, physicians, policymakers, organizations, and experts in the field and join global conversations as we elevate and raise awareness about liver health.

Thought Leadership
Donna Cryer, GLI President and CEO, delivered presentations to add GLI’s voice, advocacy, testimony, and dialogue to the most influential liver health conferences and meetings around the world.

- Inova Fairfax Medical Campus, Betty and Guy Beauty Center for Integrated Research and the Department of Medicine, lunch and learn event on liver disease clinical research and patient care; speaker
- The Forum for Collaborative Research at University of California-Berkeley, virtual discussion on the impact of COVID-19 on NASH and PSC clinical trials; panelist
- Radio tour with Wayne Eskridge, founder of the Fatty Liver Foundation, on NASH and COVID-19
- Wilton Park Virtual Dialogue, in partnership with the EASL International Liver Foundation, “Consensus for Care Pathways for NAFLD/NASH,” participant
- Zyus Cadila’s 4TH NAFLD/Nonalcoholic Fatty Liver Disease (NAFLD) Conference, “Disease Management: A Patient-Centric Approach,” keynote speaker
- Biologics Prescribers Collaborative, panelist, panel on COVID-19, the disruption of care, and the impact on biologic medicines, panelist
- Healthcare Busineswomen’s Association, Career Conversations webinar series, speaker
- Carium webinar series “Health IRL: A Collaborative Health Conversation,” on “Let’s Talk Redefining the Patient-Provider Partnership,” speaker
- Global Genes Livestream: A RARE Patient Advocacy (un) Summit panel, “Engaging Diverse Voices at the Research Table,” speaker
- The Clinical Trials Transformation Initiative at DPHARM, panel, “A Vision for Clinical Trials in 2030 - Top 5 Countdown,” at DPHARM, keynote speaker, co-presenter
- BIO Patient Advocacy Coffee Chat series, “Overview of COVID-19 program and partnerships to focus on COVID in communities of color,” panelist
- Rodham Institute at The George Washington University’s Impact Speaker Series panel, “Loving Your Liver: A Non-Toxic Relationship,” speaker
- Alliance for Health Policy Voice of the Patient Summit, “The Importance of the Patient Voice in Healthcare,” keynote speaker
- AcademyHealth discussion, “Learning from COVID-19 to Achieve Equitable, High-Value Care: Promoting Health System/Research Partnerships and Collaborations,” speaker
- Council of Medical Specialty Societies 2020 Virtual Annual Meeting, “Patient Voice on Digital Transformation,” keynote speaker
- AASLD’s The Liver Meeting Digital Experience™, “Interactive Patient-Focused Abstract Tour: Public Health/Public Equity/Health Care Delivery,” moderator/guide
- AASLD’s The Liver Meeting Digital Experience™ Annual Patients Forum, co-moderator
- 3rd Swiss Autoimmune Liver Disease Meeting, virtual conference, speaker, concluding remarks
- The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard in collaboration with the FDA conference, “Heterogeneity of Treatment Effects in Clinical Trials: Methods and Innovations,” speaker
- 4th Annual NASH Summit, Patient & Caregiver Fireside Chat, “Outlook for 2021 from the Perspective of Patients & Caregivers,” speaker and moderator
- “Surfing the NASH Tsunami” podcast guest, 11 episodes
- Host of the GLI LIVE weekly talk show, 34 episodes
## Financial Highlights

### ASSETS

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$510,889</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>53,250</td>
</tr>
<tr>
<td>Other Current Assets</td>
<td>6,594</td>
</tr>
<tr>
<td>Fixed Assets - Net</td>
<td>891</td>
</tr>
<tr>
<td>Other Assets</td>
<td>20,829</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>592,454</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable and Accrued Expenses</td>
<td>41,067</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>405,744</td>
</tr>
<tr>
<td>Loan Payable - PPP Loan</td>
<td>64,880</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>511,691</strong></td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td><strong>80,762</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td><strong>592,454</strong></td>
</tr>
</tbody>
</table>

### REVENUE

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memberships</td>
<td>396,565</td>
</tr>
<tr>
<td>Contributions - Unrestricted</td>
<td>844,312</td>
</tr>
<tr>
<td>Contributions - Restricted</td>
<td>190,000</td>
</tr>
<tr>
<td>Sponsorships</td>
<td>304,980</td>
</tr>
<tr>
<td>Other Revenues</td>
<td>12,947</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td><strong>1,748,804</strong></td>
</tr>
</tbody>
</table>

### EXPENSES

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs and Grants</td>
<td>1,236,010</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>451,754</td>
</tr>
<tr>
<td>Fundraising</td>
<td>59,190</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>1,746,955</strong></td>
</tr>
</tbody>
</table>

### CHANGE IN NET ASSETS

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NET ASSETS, BEGINNING OF YEAR</strong></td>
<td><strong>78,913</strong></td>
</tr>
<tr>
<td><strong>NET ASSETS, END OF YEAR</strong></td>
<td><strong>$80,762</strong></td>
</tr>
</tbody>
</table>

### GLI 2020 Revenue Type

- **Sponsorship**: 17.4%
- **Membership**: 22.7%
- **Program Service Fee**: Individual 1.7%
- **Grants**: 46.6%

### Amount

- **Fundraising**: 2.3%
- **COVID-19**: 9.6%
- **Pediatric and Rare**: 9.6%
- **International NASH**: 8.9%
- **NASH**: 43.5%
- **Liver Cancer**: 15.2%
- **Advanced Advocacy**: 12.6%
Global Liver Institute (GLI) is a 501(c)(3) tax-exempt not-for-profit organization, headquartered in Washington, D.C., United States, with offices in the U.S. and Europe. GLI’s vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact. GLI’s mission is to improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and supporting the scaling of optimal approaches to help eradicate liver diseases.